• Explore /
  • Poster
  • / Phase II randomized double blind trial of axitinib (Axi) +/- PF‑04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).

Phase II randomized double blind trial of axitinib (Axi) +/- PF‑04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

Sarmad Sadeghi

Sarmad Sadeghi

University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Sarmad Sadeghi , Rahul Atul Parikh , Denice D. Tsao-Wei , Susan G. Groshen , Ming Li , Leonard Joseph Appleman , Scott T. Tagawa , David M. Nanus , Ana M. Molina , Cheryl Kefauver , Moshe Chaim Ornstein , Brian I. Rini , Robert Dreicer , David I. Quinn , Primo "Lucky" N. Lara Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03092856

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4529)

DOI

10.1200/JCO.2022.40.16_suppl.4529

Abstract #

4529

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Chuanliang Cui

First Author: Renata Ferrarotto

First Author: Yoshihiko Tomita

First Author: Toni K. Choueiri